Drug Type Small molecule drug |
Synonyms MRX 6313, MRX6313 |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), RTK inhibitors(Receptor protein-tyrosine kinase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC28H40N6O |
InChIKeyMJSHVHLADKXCML-RQNOJGIXSA-N |
CAS Registry1429881-91-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | US | - | |
Solid tumor | Preclinical | US | - |